Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
Identifieur interne : 000196 ( Main/Exploration ); précédent : 000195; suivant : 000197Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
Auteurs : Bo Wang [République populaire de Chine] ; Diandian Li [République populaire de Chine] ; Tao Liu [République populaire de Chine] ; Haohua Wang [République populaire de Chine] ; Fengming Luo [République populaire de Chine] ; Yanbin Liu [République populaire de Chine]Source :
- BMC infectious diseases [ 1471-2334 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Association médicamenteuse (MeSH), Betacoronavirus (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Injections sous-cutanées (MeSH), Interféron alpha-2 (administration et posologie), Interféron alpha-2 (usage thérapeutique), Lopinavir (usage thérapeutique), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Ritonavir (usage thérapeutique), Sujet âgé (MeSH).
- MESH :
- administration et posologie : Interféron alpha-2.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Interféron alpha-2, Lopinavir, Ritonavir.
- Adulte d'âge moyen, Association médicamenteuse, Betacoronavirus, Femelle, Humains, Injections sous-cutanées, Mâle, Pandémies, Sujet âgé.
English descriptors
- KwdEn :
- Aged (MeSH), Betacoronavirus (MeSH), Coronavirus Infections (drug therapy), Drug Combinations (MeSH), Female (MeSH), Humans (MeSH), Injections, Subcutaneous (MeSH), Interferon alpha-2 (administration & dosage), Interferon alpha-2 (therapeutic use), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Ritonavir (therapeutic use).
- MESH :
- chemical , administration & dosage : Interferon alpha-2.
- chemical , therapeutic use : Interferon alpha-2, Lopinavir, Ritonavir.
- chemical : Drug Combinations.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Aged, Betacoronavirus, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Pandemics.
Abstract
BACKGROUND
The global pandemic of coronavirus disease 2019 (COVID-19) infection is ongoing and associated with high mortality. The aim of this study was to investigate the efficacy and safety of subcutaneous injection of interferon alpha-2b (IFN alpha-2b) combined with lopinavir/ritonavir (LPV/r) in the treatment of COVID-19 infection, compared with that of using LPV/r alone.
METHODS
Patients diagnosed with laboratory-confirmed COVID-19 infection in Wuhan Red Cross hospital during the period from January 23, 2020 to March 19, 2020 were included. The length of stay, the time to viral clearance and adverse reactions during hospitalization were compared between patients using oral LPV/r and combined therapy of LPV/r and subcutaneous injection of IFN alpha-2b.
RESULTS
A total of 22 patients were treated with LPV/r alone and 19 with combined therapy with subcutaneous injection of IFN alpha-2b. The average length of hospitalization in the combination group was shorter than that of LPV/r group (16 ± 9.7 vs 23 ± 10.5 days; P = 0.028). Moreover, the days of hospitalization in early intervention group decreased from 25 ± 8.5 days to 10 ± 2.9 days compared with delayed intervention group (P = 0.001). Combined therapy with IFN alpha-2b also significantly reduced the duration of detectable virus in the upper respiratory tract. No patient in each group was transferred to intensive care unit (ICU) or died during the treatment. There was no significant difference in the adverse effect composition between two groups.
CONCLUSIONS
Subcutaneous injection of IFN alpha-2b combined with LPV/r shortened the length of hospitalization and accelerated viral clearance in COVID-19 patients, which deserves further investigation in clinical practice.
DOI: 10.1186/s12879-020-05425-5
PubMed: 33008327
PubMed Central: PMC7530488
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.</title><author><name sortKey="Wang, Bo" sort="Wang, Bo" uniqKey="Wang B" first="Bo" last="Wang">Bo Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Li, Diandian" sort="Li, Diandian" uniqKey="Li D" first="Diandian" last="Li">Diandian Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Tao" sort="Liu, Tao" uniqKey="Liu T" first="Tao" last="Liu">Tao Liu</name><affiliation wicri:level="1"><nlm:affiliation>The Red Cross Hospital of Wuhan (The Eleventh Hospital of Wuhan City), Wuhan, 430015, Hubei, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Red Cross Hospital of Wuhan (The Eleventh Hospital of Wuhan City), Wuhan, 430015, Hubei</wicri:regionArea><wicri:noRegion>Hubei</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Haohua" sort="Wang, Haohua" uniqKey="Wang H" first="Haohua" last="Wang">Haohua Wang</name><affiliation wicri:level="1"><nlm:affiliation>West China School of Medicine, Sichuan University, Chengdu, 610041, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>West China School of Medicine, Sichuan University, Chengdu, 610041</wicri:regionArea><wicri:noRegion>610041</wicri:noRegion></affiliation></author><author><name sortKey="Luo, Fengming" sort="Luo, Fengming" uniqKey="Luo F" first="Fengming" last="Luo">Fengming Luo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Yanbin" sort="Liu, Yanbin" uniqKey="Liu Y" first="Yanbin" last="Liu">Yanbin Liu</name><affiliation wicri:level="1"><nlm:affiliation>Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. dr_liuyanbin@foxmail.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33008327</idno><idno type="pmid">33008327</idno><idno type="doi">10.1186/s12879-020-05425-5</idno><idno type="pmc">PMC7530488</idno><idno type="wicri:Area/Main/Corpus">000026</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000026</idno><idno type="wicri:Area/Main/Curation">000026</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000026</idno><idno type="wicri:Area/Main/Exploration">000026</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.</title><author><name sortKey="Wang, Bo" sort="Wang, Bo" uniqKey="Wang B" first="Bo" last="Wang">Bo Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Li, Diandian" sort="Li, Diandian" uniqKey="Li D" first="Diandian" last="Li">Diandian Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Tao" sort="Liu, Tao" uniqKey="Liu T" first="Tao" last="Liu">Tao Liu</name><affiliation wicri:level="1"><nlm:affiliation>The Red Cross Hospital of Wuhan (The Eleventh Hospital of Wuhan City), Wuhan, 430015, Hubei, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Red Cross Hospital of Wuhan (The Eleventh Hospital of Wuhan City), Wuhan, 430015, Hubei</wicri:regionArea><wicri:noRegion>Hubei</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Haohua" sort="Wang, Haohua" uniqKey="Wang H" first="Haohua" last="Wang">Haohua Wang</name><affiliation wicri:level="1"><nlm:affiliation>West China School of Medicine, Sichuan University, Chengdu, 610041, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>West China School of Medicine, Sichuan University, Chengdu, 610041</wicri:regionArea><wicri:noRegion>610041</wicri:noRegion></affiliation></author><author><name sortKey="Luo, Fengming" sort="Luo, Fengming" uniqKey="Luo F" first="Fengming" last="Luo">Fengming Luo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Yanbin" sort="Liu, Yanbin" uniqKey="Liu Y" first="Yanbin" last="Liu">Yanbin Liu</name><affiliation wicri:level="1"><nlm:affiliation>Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. dr_liuyanbin@foxmail.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author></analytic><series><title level="j">BMC infectious diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Combinations (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Injections, Subcutaneous (MeSH)</term><term>Interferon alpha-2 (administration & dosage)</term><term>Interferon alpha-2 (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Ritonavir (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Association médicamenteuse (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Injections sous-cutanées (MeSH)</term><term>Interféron alpha-2 (administration et posologie)</term><term>Interféron alpha-2 (usage thérapeutique)</term><term>Lopinavir (usage thérapeutique)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Ritonavir (usage thérapeutique)</term><term>Sujet âgé (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Interferon alpha-2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Interferon alpha-2</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Combinations</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Interféron alpha-2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Interféron alpha-2</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Betacoronavirus</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Association médicamenteuse</term><term>Betacoronavirus</term><term>Femelle</term><term>Humains</term><term>Injections sous-cutanées</term><term>Mâle</term><term>Pandémies</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The global pandemic of coronavirus disease 2019 (COVID-19) infection is ongoing and associated with high mortality. The aim of this study was to investigate the efficacy and safety of subcutaneous injection of interferon alpha-2b (IFN alpha-2b) combined with lopinavir/ritonavir (LPV/r) in the treatment of COVID-19 infection, compared with that of using LPV/r alone.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Patients diagnosed with laboratory-confirmed COVID-19 infection in Wuhan Red Cross hospital during the period from January 23, 2020 to March 19, 2020 were included. The length of stay, the time to viral clearance and adverse reactions during hospitalization were compared between patients using oral LPV/r and combined therapy of LPV/r and subcutaneous injection of IFN alpha-2b.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 22 patients were treated with LPV/r alone and 19 with combined therapy with subcutaneous injection of IFN alpha-2b. The average length of hospitalization in the combination group was shorter than that of LPV/r group (16 ± 9.7 vs 23 ± 10.5 days; P = 0.028). Moreover, the days of hospitalization in early intervention group decreased from 25 ± 8.5 days to 10 ± 2.9 days compared with delayed intervention group (P = 0.001). Combined therapy with IFN alpha-2b also significantly reduced the duration of detectable virus in the upper respiratory tract. No patient in each group was transferred to intensive care unit (ICU) or died during the treatment. There was no significant difference in the adverse effect composition between two groups.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Subcutaneous injection of IFN alpha-2b combined with LPV/r shortened the length of hospitalization and accelerated viral clearance in COVID-19 patients, which deserves further investigation in clinical practice.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">33008327</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.</ArticleTitle><Pagination><MedlinePgn>723</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-020-05425-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The global pandemic of coronavirus disease 2019 (COVID-19) infection is ongoing and associated with high mortality. The aim of this study was to investigate the efficacy and safety of subcutaneous injection of interferon alpha-2b (IFN alpha-2b) combined with lopinavir/ritonavir (LPV/r) in the treatment of COVID-19 infection, compared with that of using LPV/r alone.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients diagnosed with laboratory-confirmed COVID-19 infection in Wuhan Red Cross hospital during the period from January 23, 2020 to March 19, 2020 were included. The length of stay, the time to viral clearance and adverse reactions during hospitalization were compared between patients using oral LPV/r and combined therapy of LPV/r and subcutaneous injection of IFN alpha-2b.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 22 patients were treated with LPV/r alone and 19 with combined therapy with subcutaneous injection of IFN alpha-2b. The average length of hospitalization in the combination group was shorter than that of LPV/r group (16 ± 9.7 vs 23 ± 10.5 days; P = 0.028). Moreover, the days of hospitalization in early intervention group decreased from 25 ± 8.5 days to 10 ± 2.9 days compared with delayed intervention group (P = 0.001). Combined therapy with IFN alpha-2b also significantly reduced the duration of detectable virus in the upper respiratory tract. No patient in each group was transferred to intensive care unit (ICU) or died during the treatment. There was no significant difference in the adverse effect composition between two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Subcutaneous injection of IFN alpha-2b combined with LPV/r shortened the length of hospitalization and accelerated viral clearance in COVID-19 patients, which deserves further investigation in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Diandian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Red Cross Hospital of Wuhan (The Eleventh Hospital of Wuhan City), Wuhan, 430015, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haohua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>West China School of Medicine, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Fengming</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yanbin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. dr_liuyanbin@foxmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Interferon alpha-2b</Keyword><Keyword MajorTopicYN="N">Subcutaneous injection</Keyword><Keyword MajorTopicYN="N">Viral clearance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>3</Day><Hour>5</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33008327</ArticleId><ArticleId IdType="doi">10.1186/s12879-020-05425-5</ArticleId><ArticleId IdType="pii">10.1186/s12879-020-05425-5</ArticleId><ArticleId IdType="pmc">PMC7530488</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):590-592</Citation><ArticleIdList><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 30;395(10238):1695-1704</Citation><ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Ther. 2020;14(1):58-60</Citation><ArticleIdList><ArticleId IdType="pubmed">32147628</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation><ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar;55(3):105924</Citation><ArticleIdList><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):69-71</Citation><ArticleIdList><ArticleId IdType="pubmed">31996494</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Jun;178:104791</Citation><ArticleIdList><ArticleId IdType="pubmed">32275914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation><ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2018 May;28(3):e1977</Citation><ArticleIdList><ArticleId IdType="pubmed">29664167</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Wang, Bo" sort="Wang, Bo" uniqKey="Wang B" first="Bo" last="Wang">Bo Wang</name></noRegion><name sortKey="Li, Diandian" sort="Li, Diandian" uniqKey="Li D" first="Diandian" last="Li">Diandian Li</name><name sortKey="Liu, Tao" sort="Liu, Tao" uniqKey="Liu T" first="Tao" last="Liu">Tao Liu</name><name sortKey="Liu, Yanbin" sort="Liu, Yanbin" uniqKey="Liu Y" first="Yanbin" last="Liu">Yanbin Liu</name><name sortKey="Luo, Fengming" sort="Luo, Fengming" uniqKey="Luo F" first="Fengming" last="Luo">Fengming Luo</name><name sortKey="Wang, Haohua" sort="Wang, Haohua" uniqKey="Wang H" first="Haohua" last="Wang">Haohua Wang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000196 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000196 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33008327
|texte= Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33008327" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |